BHVN Biohaven Ltd. Insider Trading

VP/CAO Clark George C. buys 17,000 BHVN shares at $8.52; stock down 80.7% from 52-week high, cluster of 4 insider buys in 14 days.

Clark George C., VP and Chief Accounting Officer, purchased 17,000 shares at $8.52 on 2025-11-17 for $144,770.30, increasing his holdings 566.7% to 20,000 shares post-transaction. The purchase occurs against a backdrop of sharp deterioration: the stock is down 80.7% from its 52-week high of $49.04 and has declined 40.8% in the past 30 days. Notably, this transaction is part of a cluster buy pattern—3 other insiders also acquired shares within the past 14 days. The company reported negative net income of $-173,443,000.00 in its most recent fiscal year, signaling fundamental financial stress. The convergence of multiple insiders purchasing at heavily depressed prices while the company operates unprofitably warrants investor scrutiny into whether management perceives genuine value recovery or is responding to external pressures.

Director John W. Childs bought 3,333,333 shares (3.33M) of BHVN at $7.50 for $25.0M on 2025-11-13; stock now $8.27, off 83.6% from 52-week high.

John W. Childs, a director at Biohaven, purchased 3,333,333 shares at $7.50, bringing his holdings from 2,320,571 to 5,653,904 shares—a 143.6% increase in his stake. This large acquisition occurs as the stock trades down 83.6% from its 52-week high of $50.36 and has fallen 48.2% in the past 30 days. His prior trades at BHVN show a concerning pattern: 5 earlier purchases all resulted in negative 90-day returns ranging from -23.1% to -49.0%, with zero instances of profitable 90-day outcomes post-purchase. The company reported a net loss of $173,443,000 over its most recent full fiscal year, underlining fundamental challenges. A cluster of 3 other insiders also purchased within the past 14 days, suggesting coordinated or reactive positioning rather than an isolated conviction signal.

CEO Coric Vlad purchased 666,666 shares at $7.50 for $4,999,995.00; holdings surge 902.4%; cluster buy pattern with 3 other insiders in 14 days

Coric Vlad, CEO of Biohaven Ltd., executed two separate purchases totaling 666,666 shares at $7.50 on 2025-11-13, expanding his holdings from 73,880 shares to 740,546 shares—a 902.4% increase. The transaction occurred against a backdrop of significant price weakness: the stock is down 83.6% from its 52-week high of $50.36 and down 48.2% over the past 30 days, placing this purchase near recent lows. This activity is reinforced by a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated confidence or response to company developments rather than an isolated insider action. However, Biohaven is operating at a substantial loss, with full-year net income of $-173,443,000.00, and the CEO's same-ticker purchase history at Biohaven shows mixed outcomes—2 of 4 prior buys at this ticker yielded positive 90-day returns, while 2 saw 30-day declines. The confluence of a cluster buy by leadership during a sharp drawdown in an unprofitable company warrants close attention to underlying catalysts.

Director Bailey Gregory bought 400,000 shares of BHVN at $7.50 (Nov 13); stock now $8.27, down -83.6% from 52-week high of $50.36.

Bailey Gregory, a Director, purchased 400,000 shares at $7.50 on 2025-11-13, increasing his holdings by 24.7% to 2.02M shares. The stock has declined sharply: it stands at $8.27 today, representing a -83.6% drop from its 52-week high of $50.36, and has fallen -48.2% over the past 30 days. Biohaven is unprofitable, with net income of $-173.4M for the full fiscal year and a market cap of $875.4M. Critically, Gregory's historical track record at BHVN shows poor timing: of his four prior buys at this ticker, only 1 of 4 was well-timed at the 90-day mark, with an average 90-day return across those trades of -5.5%. The current purchase coincides with a cluster buy pattern—3 other insiders also bought within the past 14 days—yet this cluster activity occurs during a period of severe stock depreciation and fundamental unprofitability, making it difficult to draw a confidence signal from the timing alone.

Director Childs buys 32,700 shares for $996.2K at $30.47 avg; stock -48.2% from 52-week high, 3 of 4 prior BHVN buys well-timed at 90d mark.

CHILDS JOHN W (Director) executed 4 separate purchases totaling 32,700 shares for $996,238.47 at a blended average price of $30.47 on 2025-03-04. The transaction occurred as the stock trades at $30.97, down -48.2% from its 52-week high of $59.75 and -17.9% over the past 30 days. Historically, his prior BHVN trades demonstrate a strong pattern of well-timed purchases: 3 of 4 measurable prior buys showed positive 90-day returns, including a +44.3% gain after his 2024-07-18 purchase and +15.3% and +10.6% gains after his May 2024 buys. The company reported a net loss of $160,304,000.00 in its most recent full fiscal year and carries a $3.2B market cap. The combination of a substantial acquisition at depressed price levels, convergence with his historical pattern of timely entry points at BHVN specifically, and the magnitude of the stake positions this as a noteworthy conviction signal that merits close monitoring.

Director John W. Childs bought 29,000 shares of BHVN at $35.94 on 2024-12-30 despite stock down 37.5% from 52-week high and company's $-160.3M net loss

Director John W. Childs purchased 29,000 shares at $35.94 on 2024-12-30, adding to a substantial position of 2.37M shares total. The buy occurred as BHVN traded at -37.5% from its 52-week high and -18.8% over the prior 30 days, while the company reported a full-year net income of $-160.3M. Historically, Childs's same-ticker buys at BHVN show mixed results: 3 of 5 prior purchases generated positive 90-day returns (July 2024 +44.3%, May 30 +15.3%, May 13 +10.6%), while 2 posts declines (April 2024 -12.2%, October 2024 -21.4%). His broader cross-ticker track record reflects stronger discipline: 11 prior open-market buys achieved 63.64% 90-day win rate with +26.9% average 90-day return. The current transaction's signal depends on whether this represents conviction in a turnaround or routine portfolio maintenance amid unprofitability.

Coric Vlad (CEO) purchases 21,052 BHVN shares at $47.50; cluster buy pattern with 2 other insiders in 14 days

CEO Coric Vlad purchased 21,052 shares at $47.50 on 2024-10-02, increasing his stake by 2.5% to 861,942 shares. The purchase occurred as the stock was at -21.9% from its 52-week high but up +22.2% over the prior 30 days, and coincided with 2 other insiders buying within the past 14 days—a cluster pattern that may signal synchronized confidence in near-term prospects. However, Vlad's same-ticker history at BHVN shows mixed timing: his April 2024 buy declined -7.3% over 30 days, while his October 2023 purchases gained +40.1% at 30 days; only 2 of his 3 prior BHVN trades were well-timed at the 90-day mark. The company remains unprofitable with net income of $-319,771,000.00 over its most recent full fiscal year, a fundamental headwind that offsets any positive reading from the insider cluster and recent price momentum.

Director John W. Childs bought 21,052 shares of BHVN at $47.50 for $999,970.00 on 2024-10-02; cluster buy with 2 other insiders.

Director John W. Childs purchased 21,052 shares at $47.50 on 2024-10-02, representing his first open-market accumulation at BHVN (zero prior holdings). His cross-ticker track record shows 10 prior buys with a 90d win rate of 66.67% and an average 90d return of +30.3%, though at BHVN specifically, his 4 prior measurable buys produced mixed results: 2 of 4 showed well-timed entry (positive 90d outcomes), while 2 of 4 underperformed at the 90-day mark. The current price of $46.65 is -21.9% from the 52-week high of $59.75 but +22.2% over the past 30 days and +36.9% over 90 days, indicating recent momentum recovery. Notably, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern. The company remains unprofitable with a net income of $-319,771,000.00 against a market cap of $4,410,396,102.45, adding context to the director's entry decision despite negative fundamentals.

Director Bailey Gregory buys 5,000 BHVN shares at $44.19 on 2024-09-24; stock up +18.5% in 30 days, +40.3% in 90 days post-transaction.

Bailey Gregory, a director at Biohaven Ltd., purchased 5,000 shares at $44.19 for a total value of $220,966.00 on 2024-09-24, adding to holdings of 1,620,071 shares post-transaction. The stock has appreciated significantly since the purchase, trading +18.5% over the subsequent 30 days and +40.3% over 90 days, with current price at $49.23. Among Gregory's prior trades at BHVN (4 distinct transactions), the timing pattern is mixed: two of four prior buys showed positive 90-day returns (the 2024-05-13 buy posted +13.8%, and the 2023-10-04 buy posted +85.8%), while two showed negative 90-day outcomes. However, this recent purchase was made into a company carrying a net loss of $-319,771,000.00 across its most recent full fiscal year, warranting scrutiny of the underlying business fundamentals alongside the positive stock momentum.

Director John W. Childs buys 28,400 BHVN shares at $35.67; cross-ticker track record shows 100% 90d win rate, but BHVN-specific prior buys all negative at 30d.

Director John W. Childs purchased 28,400 shares of Biohaven at $35.67 on 2024-07-18, adding to a substantial 2.34M share position. His cross-ticker track record across all open-market transactions shows a strong 100% win rate over 90 days with an average 90-day return of +71.0%. However, this same-ticker history at BHVN presents a contrasting picture: his five prior purchases (all in April and May 2024) have each posted negative 30-day returns ranging from -2.4% to -7.3%, with no measurable 90-day outcomes yet available. The company remains deeply unprofitable with a net loss of $-179,504,000.00 in its most recent full fiscal year. This transaction places an otherwise successful insider's recent BHVN activity in tension with his strong historical track record elsewhere.